Logo
U.S. TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET ANALYSIS
  2. / Market Insights
  3. U.S. Transthyretin Amyloidosis Treatment Market Analysis
all report title image

U.S. TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET ANALYSIS

U.S. Transthyretin Amyloidosis Treatment Market, By Type (Hereditary Transthyretin Amyloidosis (hATTR-CM) and Wild Type Amyloidosis), By Drug Type (Tafamidis, Diflunisal, Inotersen, Patisiran, Tolcapone, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)

  • Published In : Nov 2024
  • Code : CMI1919
  • Pages :116
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Market Concentration and Competitive Landscape

U.S. Transthyretin Amyloidosis Treatment Market Concentration By Players

Close-monitor your Competitor's Move, Get Instant Access to the Report

Key Players Insights
    • Alnylam Pharmaceuticals, Inc.
    • Pfizer, Inc.
    • Prothena Corporation Plc
    • GSK plc
    • Ionis Pharmaceuticals, Inc.
    • SOM Innovation Biotech, S.L.
    • Eidos Therapeutics
    • BridgeBio Pharma, Inc.
    • Bristol-Myers Squibb Company
    • AstraZeneca
    • Acrotech Biopharma
    • Attralus, Inc.

    • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now

    Press Release

    U.S. Transthyretin Amyloidosis Treatment Market to surpass USD 111.9 Mn by 2031.
    Logo

    Credibility and Certifications

    ESOMAR
    DUNS Registered
    Clutch
    DMCA Protected

    9001:2015

    Credibility and Certifications

    27001:2022

    Credibility and Certifications

    EXISTING CLIENTELE

    Joining thousands of companies around the world committed to making the Excellent Business Solutions.

    View All Our Clients
    trusted clients logo
    © 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.